https://scholars.lib.ntu.edu.tw/handle/123456789/634649
標題: | Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis | 作者: | Liam, Chong Kin Ahmad, Azura Rozila Hsia, Te-Chun Zhou, Jianying Kim, Dong-Wan Soo, Ross Andrew Cheng, Ying Lu, Shun Shin, Sang Won CHIH-HSIN YANG Zhang, Yiping Zhao, Jun Berghoff, Karin Bruns, Rolf Johne, Andreas Wu, Yi-Long |
公開日期: | 15-五月-2023 | 卷: | 29 | 期: | 10 | 來源出版物: | Clinical cancer research : an official journal of the American Association for Cancer Research | 摘要: | The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3, 2021). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634649 | ISSN: | 10780432 | DOI: | 10.1158/1078-0432.CCR-22-3318 |
顯示於: | 醫學院附設癌醫中心醫院(臺大癌醫) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。